NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

腺苷酸A3受體 (ADORA3) - 開發中產品分析

Adenosine Receptor A3 - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 358700
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
腺苷酸A3受體 (ADORA3) - 開發中產品分析 Adenosine Receptor A3 - Pipeline Review, H2 2020
出版日期: 2020年10月30日內容資訊: 英文 89 Pages
簡介

腺苷酸A3受體,又被稱之為ADORA3,是腺苷酸受體。腺苷酸A3受體可在心缺血的時候持續性介入心臟保護功能,是G蛋白偶聯受體 (GPCR) 。

本報告提供腺苷酸A3受體 (ADORA3)的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Can-Fite BioPharma Ltd.
  • Huons Co., Ltd.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2648TDB

Summary:

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 - Pipeline Review, H2 2020, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1, 6, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Immunology, Gastrointestinal, Metabolic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Male Health, Oncology, Ophthalmology, Infectious Disease, Musculoskeletal Disorders, Respiratory and Women's Health which include indications Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Glaucoma, Inflammation, Kidney Fibrosis, Rheumatoid Arthritis, Arthritis, Autoimmune Disorders, Chemotherapy Induced Pain, Chronic Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Coronavirus Disease 2019 (COVID-19), Erectile Dysfunction, Female Sexual Dysfunction, Hepatocellular Carcinoma, Inflammatory Pain, Liver Cancer, Male Sexual Dysfunction, Melanoma, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
  • The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Adenosine Receptor A3 (ADORA3) - Overview
  • Adenosine Receptor A3 (ADORA3) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
  • BioIntervene Inc
  • Can-Fite BioPharma Ltd
  • Future Medicine Co Ltd
  • Palo BioFarma SL
  • Adenosine Receptor A3 (ADORA3) - Drug Profiles
  • BIO-205 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CF-602 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FM-1203 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FM-1302 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LJ-1888 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LJ-2698 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • namodenoson - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PBF-1650 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PBF-677 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • piclidenoson - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmonary Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Autoimmune Disorders, Inflammation, Liver Cancer and Metabolic Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize ADORA3 for Chronic Inflammation and Neurodegenerative Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Adenosine Receptor A3 (ADORA3) - Dormant Products
  • Adenosine Receptor A3 (ADORA3) - Discontinued Products
  • Adenosine Receptor A3 (ADORA3) - Product Development Milestones
  • Featured News & Press Releases
  • Sep 30, 2020: Can-Fite selected to deliver late-breaking oral presentation on Namodenoson's treatment of NASH at American Association for the Study of Liver Diseases Conference
  • Aug 31, 2020: FDA clears Can-Fite to commence phase II COVID-19 study
  • Aug 25, 2020: Can-Fite receives notification of patent grant from European Patent Office for Namodenoson in the treatment of NASH
  • Jul 27, 2020: Can-Fite submits Investigational New Drug Application to U.S. FDA for COVID-19 phase II Study
  • Jul 20, 2020: Can-Fite completes development of an assay to identify clinically active cannabis derived compounds
  • Jul 15, 2020: Can-Fite completes phase II COVID-19 protocol based on FDA guidance, plans to file IND shortly
  • Jun 30, 2020: Can-Fite announces final data analysis from phase II NASH study: Highly significant and sustained reduction in liver fat volume throughout study period
  • Jun 09, 2020: Following Pre-IND guidance from FDA Can-Fite to Advance Piclidenoson into phase II COVID-19 trial in the U.S.
  • Jun 08, 2020: Can-Fite participating in BIO Digital International Convention and One-on-One partnering meetings on June 8-12, 2020
  • Jun 05, 2020: Can-Fite plans Phase III liver cancer trial of Namodenoson in Europe
  • May 21, 2020: Can-Fite receives notice of allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
  • May 18, 2020: Can-Fite reports additional findings from successful phase II NASH Study: 25 mg Dose of namodenoson significantly reduced liver fat and fibrosis
  • May 15, 2020: Can-Fite announces pre-IND submission to U.S. FDA for Piclidenoson in the treatment of covid-19 infected patients with moderate-to-severe symptoms
  • Apr 14, 2020: Can Fite to conduct investor call to review positive phase II NASH data
  • Apr 13, 2020: Can Fite received approval for covid-19 clinical trial in Israel, patient enrollment and dosing to commence immediately
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by BioIntervene Inc, H2 2020
  • Pipeline by Can-Fite BioPharma Ltd, H2 2020
  • Pipeline by Future Medicine Co Ltd, H2 2020
  • Pipeline by Palo BioFarma SL, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020